ArticleScientific reports2025
Histological prognostic factors in canine appendicular osteosarcoma: 57 cases (2014-2022).
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Appendicular osteosarcoma is the most common primary malignant bone neoplasia in dogs, with a generally guarded prognosis. Multiple clinicopathological factors have been suggested to be associated with a negative prognosis in dogs with osteosarcoma. The objective of this study was to identify histopathological prognostic factors in canine appendicular osteosarcoma. We hypothesize that the presence of microvascular invasion and certain histological subtypes will negatively impact prognosis. Dogs with surgically resected primary appendicular osteosarcoma were enrolled. The following histopathological results were recorded: subtype of osteosarcoma (chondroblastic, osteoblastic, fibroblastic, giant cell, telangiectatic, poorly differentiated, combined), presence of microvascular invasion, lymphatic invasion, and completeness of surgical margin. Survival analysis was performed to evaluate disease outcome associations with histopathological data. Fifty-seven dogs were included. The majority (43) of dogs had osteoblastic osteosarcoma. Only two dogs had chondroblastic osteosarcoma, one dog had giant cell osteosarcoma, and no dog had fibroblastic or poorly differentiated osteosarcoma. Microvascular invasion was evident in 5 dogs. There was no significant difference in progression-free interval (PFS) or overall survival time (OST) between tumor subtypes. There was also no difference in PFS and OST with tumoral microvascular invasion (median 271 days and 168 days, respectively) or without microvascular invasion (median 209 days and 262 days, respectively). Neither microvascular invasion nor histologic subtype were significantly associated with outcome in dogs with appendicular osteosarcoma. Further evaluation of subtype as a prognostic indicator is warranted, given the predominance of a single subtype in this study. The clinical significance of osteosarcoma subtypes as a prognosticator needs further evaluation based on this study given the predominance of a single subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.